LONDON (Reuters) – Despite austerity-driven cuts across European healthcare systems, most countries have been slow to embrace a new class of medicines that could save them billions of euros – copies of biotech treatments.
These cheaper versions of expensive biotech drugs, known as biosimilars, could slash the cost of treating diseases like cancer and rheumatoid arthritis in the same way that generics have curbed spending on traditional medicines.
LONDON, Dec 3 (Reuters) – The number of new drugs approved
for sale by regulators may be rising but manufacturers are still
struggling to get a decent bang for their research buck,
according to a report on Tuesday.
The global pharmaceuticals industry is trying to replenish
its medicine chest after a wave of patent expiries that peaked
in 2012. Optimism has been growing that the industry might have
been getting the formula right as more products, especially for
cancer and rare diseases, win approval.
BEIJING/LONDON (Reuters) – British Prime Minister David Cameron raised GlaxoSmithKline’s (GSK.L: Quote, Profile, Research, Stock Buzz) problems in China – where it is being investigated for alleged bribery – with political leaders on Monday as the drugmaker emphasized its commitment to doing business there.
Cameron, who is visiting China with executives including GSK chief executive Andrew Witty, discussed the company’s dilemma with China’s leaders and stressed the need for a stable, predictable business environment, a person familiar with the matter said.
LONDON (Reuters) – Novo Nordisk is about to launch a mid-stage clinical study with a tablet version of a so-called GLP-1 medicine as it steps up the hunt for diabetes pills that can replace injections.
The Phase II trial may start as early as next week and will involve approximately 600 patients, Chief Science Officer Mads Krogsgaard Thomsen said on Thursday.
OSLO/LONDON, Nov 26 (Reuters) – Bayer has offered
to pay $2.4 billion for Norway’s Algeta, its partner
for a new prostrate cancer treatment, a 27 percent premium to
the stock’s last close, Algeta said on Tuesday.
The deal would give Bayer outright control over Xofigo, a
drug the two have developed jointly since 2009 and started
selling in the United States this year.
LONDON, Nov 22 (Reuters) – Biogen Idec has won
regulatory protection for its top-selling multiple sclerosis
drug Tecfidera in Europe, paving the way for its launch in
markets that could account for a large proportion of future
The European Medicines Agency said on Friday it had granted
the oral medicine a “new active substance” (NAS) designation,
securing Biogen 10 years protection through data exclusivity
that will stop generic firms from launching copycat versions.
LONDON (Reuters) – Novartis is hot on the heels of Pfizer in developing a promising new type of breast cancer drug that analysts believe could generate billions of dollars in annual sales.
The Swiss drugmaker, which has previously kept its research program under wraps, revealed on Friday that its experimental pill LEE011 was set to enter final-stage Phase III clinical trials next month.